Daratumumab and Eltrombopag for Pure Red Cell Aplasia Post ABO Incompatible Allogeneic Hematopoietic Stem Cell Transplant for Acute Lymphoblastic Leukemia.

IF 1.5 4区医学 Q3 HEMATOLOGY

Turkish Journal of Hematology Pub Date : 2024-11-18 DOI:10.4274/tjh.galenos.2024.2024.0231

Mehmet Sezgin Pepeler, Simten Dagdas, Emel İşleyen, Gaye Katayıfçı, Aydan Kılıçarslan, Esra Özhamam, Muhammed Talha Adakul, Fahir Öztürk, Funda Ceran, Gülsüm Özet

引用次数: 0

查看原文本刊更多论文

Daratumumab 和 Eltrombopag 用于治疗急性淋巴细胞白血病 ABO 不相容异基因造血干细胞移植后的纯红细胞再生障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Hematology HEMATOLOGY-

CiteScore

2.90

自引率

3.80%

发文量

审稿时长

1 months

期刊介绍： The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology. The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.